tag:blogger.com,1999:blog-4230162007222918868.post7877797926621741532..comments2023-09-19T05:50:03.130-04:00Comments on Renal Fellow Network: Extended-Release Tacrolimus: same old drug in a different package?Gearoid McMahonhttp://www.blogger.com/profile/08049723797363526138noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-4230162007222918868.post-68011908734808594802013-12-17T08:47:26.752-05:002013-12-17T08:47:26.752-05:00I agree. If patients are still on mycophenolate, t...I agree. If patients are still on mycophenolate, they will still be on twice-daily dosing regardless of the use of extended release tacrolimus. A small subset of patients on daily azathioprine as an anti metabolite agent d/t intolerance of mycophenolate (GI issues?) may have a compliance benefit.Miae Kimnoreply@blogger.comtag:blogger.com,1999:blog-4230162007222918868.post-70295083805292731852013-12-17T08:45:49.161-05:002013-12-17T08:45:49.161-05:00I am not aware of a study that looked at the safet...I am not aware of a study that looked at the safety or pharmacokinetics of extended release tacrolimus in patients of African descent. Considering that the metabolism/distribution of extended release tacrolimus formulations are also affected by 3A4 and P-gp, they may be likely to deal with low troughs or AUC. Does anyone have experience using tacrolimus in this population?Miae Kimnoreply@blogger.comtag:blogger.com,1999:blog-4230162007222918868.post-21131085563685013562013-12-13T14:30:50.515-05:002013-12-13T14:30:50.515-05:00Also from a pratcial point of view, another reason...Also from a pratcial point of view, another reason it never took off in Europe was that patients are also on MMF so still have to take BID meds. Anonymoushttps://www.blogger.com/profile/08638098059713634650noreply@blogger.comtag:blogger.com,1999:blog-4230162007222918868.post-46314760693269164672013-12-13T10:23:59.350-05:002013-12-13T10:23:59.350-05:00This drug has been used for years in Europe. Howev...This drug has been used for years in Europe. However, given the issues around p-glycoprotein and cytochrome p450 activity in AA compared to European Americans, I wonder if its safety profile is different in the US population. Has this been looked at specifically in patients with African heritage?Gearoid McMahonhttps://www.blogger.com/profile/08049723797363526138noreply@blogger.com